Sepsis and Septic Shock: Current Treatment Strategies and New Approaches.

Sepsis is a complex condition characterized by the simultaneous activation of inflammation and coagulation in response to microbial insult. These events manifest as systemic inflammatory response syndrome or sepsis symptoms through the release of proinflammatory cytokines, procoagulants, and adhesion molecules from immune cells and/or damaged endothelium. Today, sepsis is a severe multisystem disease with difficult treatments for its manifestations and high mortality rates. In the last two decades in particular, many studies have been conducted on sepsis that cause shock, multiorgan dysfunction, and organ failure by especially leading to hemodynamic changes. In sepsis, increasing antibiotic resistance and medicine-resistant hemodynamic changes have resulted in further research on new treatment modalities in addition to classical treatments. In the last decade, the sepsis physiopathology has been elucidated. Various therapeutic agents have been used in addition to antibiotherapy, but no satisfactory results have been obtained. This review summarizes the sepsis pathophysiology, current treatment protocols, and new approaches.

[1]  E. Akpinar,et al.  Comparative Study on Effects of Nebulized and Oral Salbutamol on a Cecal Ligation and Puncture-Induced Sepsis Model in Rats , 2014, Drug Research.

[2]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[3]  Jonathan Cohen The immunopathogenesis of sepsis , 2002, Nature.

[4]  K. Reinhart,et al.  Pathophysiology of Sepsis and Multiple Organ Dysfunction , 2011 .

[5]  F. Atalay,et al.  Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study , 2011, Clinical and experimental immunology.

[6]  O. Deveci,et al.  Antifungal Susceptibility and Risk Factors in Patients with Candidemia. , 2016, The Eurasian journal of medicine.

[7]  Gavin D Perkins,et al.  Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. , 2016, The New England journal of medicine.

[8]  David T. Huang,et al.  Severe sepsis and septic shock: review of the literature and emergency department management guidelines. , 2006, Annals of emergency medicine.

[9]  B. Z. Altunkaynak,et al.  &agr;-LIPOIC ACID AS A POTENTIAL TARGET FOR THE TREATMENT OF LUNG INJURY CAUSED BY CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS MODEL IN RATS , 2009, Shock.

[10]  Y. Bayir,et al.  The protective effect of amiodarone in lung tissue of cecal ligation and puncture-induced septic rats: a perspective from inflammatory cytokine release and oxidative stress , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

[11]  L. Carbonell,et al.  Oxidative stress in critically ill patients with systemic inflammatory response syndrome , 2002, Critical care medicine.

[12]  R. Hotchkiss,et al.  The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.

[13]  R. Bordet,et al.  Pretreatment with peroxysome proliferator-activated receptor α agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock , 2005, Intensive Care Medicine.

[14]  R. Balogun,et al.  Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected gram-negative sepsis. , 2005, Critical care medicine.

[15]  A. Zangrillo,et al.  Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. , 2015, Journal of critical care.

[16]  R. Bone,et al.  Gram-negative sepsis. Background, clinical features, and intervention. , 1991, Chest.

[17]  S. Atamanalp,et al.  Protective effects of lithium: a new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. , 2013, International immunopharmacology.

[18]  E. Akpinar,et al.  What is the role of renin inhibition during rat septic conditions: preventive effect of aliskiren on sepsis-induced lung injury , 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

[19]  Z. Halıcı,et al.  Evaluation of 5-HT7 Receptor Trafficking on In Vivo and In Vitro Model of Lipopolysaccharide (LPS)-Induced Inflammatory Cell Injury in Rats and LPS-Treated A549 Cells , 2017, Biochemical Genetics.

[20]  P. Gøtzsche,et al.  Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Sriskandan,et al.  The pathogenesis of septic shock. , 1995, The Journal of infection.

[22]  Mitchell M. Levy,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[23]  S. Ünal,et al.  Factors influencing prognosis in bacteremia due to gram-negative organisms: evaluation of 448 episodes in a Turkish university hospital. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[25]  Roger C. Bone Definitions for Sepsis and Organ Failure , 1993 .

[26]  W. Wiersinga,et al.  Inflammation, endothelium, and coagulation in sepsis , 2008, Journal of leukocyte biology.

[27]  K. Polderman,et al.  Drug intervention trials in sepsis: divergent results , 2004, The Lancet.

[28]  D. Remick,et al.  The pathogenesis of sepsis. , 2011, Annual review of pathology.

[29]  J. Bakker,et al.  Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.

[30]  A. Oral,et al.  The Effects of Montelukast on Antioxidant Enzymes and Proinflammatory Cytokines on the Heart, Liver, Lungs, and Kidneys in a Rat Model of Cecal Ligation and Puncture–Induced Sepsis , 2011, TheScientificWorldJournal.

[31]  D. Pittet,et al.  Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  H. Bruining,et al.  Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. , 1998, Critical care medicine.

[33]  D. Cook,et al.  Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.

[34]  S. Bhagwanjee,et al.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. , 1997, Critical care medicine.

[35]  S. Pillai,et al.  Innate immunity. , 1996, Current opinion in immunology.

[36]  C. Hinds,et al.  Anabolic strategies in critical illness. , 2002, Current opinion in pharmacology.

[37]  E. Camporesi,et al.  Hyperbaric O2 reduces intestinal ischemia-reperfusion-induced TNF-α production and lung neutrophil sequestration , 2001, European Journal of Applied Physiology.

[38]  I. İnce,et al.  Effects of Propofol and Midazolam on the Inflammation of Lungs after Intravenous Endotoxin Administration in Rats. , 2015, The Eurasian journal of medicine.

[39]  Miet Schetz,et al.  Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control* , 2003, Critical care medicine.

[40]  L. McIntyre,et al.  Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity , 2005, Canadian Medical Association Journal.

[41]  R. Bone,et al.  Sepsis: a new hypothesis for pathogenesis of the disease process. , 1997, Chest.

[42]  James A Russell,et al.  Management of sepsis. , 2006, The New England journal of medicine.

[43]  M. Berger,et al.  Improving nutritional support in critically Ill septic patients: glutamine alone or in combination? , 2002, Nutrition.

[44]  Peter A. Ward,et al.  Harmful molecular mechanisms in sepsis , 2008, Nature Reviews Immunology.